WEST PHARMACEUTICAL SERVICES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that WEST PHARMACEUTICAL SERVICES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.89B | Feb 21, 2023 |
| FY2022 | Dec 31, 2021 | $2.83B | Feb 21, 2023 |
| FY2022 | Dec 31, 2020 | $2.15B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $1.84B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $1.72B | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $1.60B | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $1.51B | Feb 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.07B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.89B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $2.95B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $2.89B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $2.83B | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $580.20M | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | $548.00M | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | $527.20M | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | $491.50M | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | $470.60M | Feb 23, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.60B | Feb 26, 2018 |
| FY2017 | Dec 31, 2016 | $1.51B | Feb 26, 2018 |
| FY2017 | Dec 31, 2015 | $1.40B | Feb 26, 2018 |
| FY2016 | Dec 31, 2014 | $1.42B | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $1.37B | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $1.27B | Feb 25, 2015 |
| FY2013 | Dec 31, 2011 | $1.19B | Feb 27, 2014 |
| FY2012 | Dec 31, 2010 | $1.10B | Feb 27, 2013 |
| FY2011 | Dec 31, 2009 | $1.06B | Mar 1, 2012 |
| FY2010 | Dec 31, 2008 | $1.05B | Feb 28, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.10B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $998.50M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.13B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.14B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.18B | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $211.10M | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | $194.60M | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | $195.10M | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | $167.00M | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | $153.20M | Feb 23, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $493.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $492.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $593.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $585.90M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $661.80M | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $98.40M | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | $82.30M | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | $91.20M | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | $74.30M | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | $63.90M | Feb 23, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $584.90M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $569.90M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $676.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $734.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $752.30M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $406.90M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $296.60M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $240.30M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $225.80M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $195.20M | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $69.10M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $68.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $58.50M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $52.80M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $46.90M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $38.90M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $40.30M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $39.10M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $36.80M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $393.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $338.50M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $353.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $316.90M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $362.80M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $302.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $272.70M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $262.90M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $246.00M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $239.60M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $754.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $653.40M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $776.50M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $724.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $584.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $472.50M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $367.20M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $288.60M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $263.30M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $219.40M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $285.90M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $377.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $362.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $284.60M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $253.40M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $174.40M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $126.40M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $104.70M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $130.80M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $170.20M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.27B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.64B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $3.83B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $3.62B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $3.31B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $2.79B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.34B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.98B | Feb 24, 2020 |
| FY2019 | Dec 31, 2017 | $1.86B | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $1.72B | Feb 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $961.10M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $948.50M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $931.90M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $978.40M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $939.30M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $768.20M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $582.60M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $582.90M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $599.20M | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.18B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.68B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $2.88B | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | $2.68B | Feb 17, 2026 |
| FY2024 | Dec 31, 2021 | $2.34B | Feb 18, 2025 |
| FY2023 | Dec 31, 2020 | $1.85B | Feb 20, 2024 |
| FY2022 | Dec 31, 2019 | $1.57B | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $1.40B | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | $1.28B | Feb 23, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.90M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $106.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $108.50M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $107.30M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $109.90M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $111.10M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $107.80M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $105.80M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $107.70M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $103.00M | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.37B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.96B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $3.52B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.99B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $2.46B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.85B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.55B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.35B | Feb 24, 2020 |
| FY2018 | Jan 1, 2018 | $1.19B | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $1.18B | Feb 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $791.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $484.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $853.90M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $894.30M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $762.60M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $615.50M | Feb 22, 2022 |
| FY2021 | Dec 31, 2019 | $439.10M | Feb 22, 2022 |
| FY2021 | Dec 31, 2018 | $337.40M | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | $235.90M | Feb 23, 2021 |
| FY2019 | Dec 31, 2016 | $203.00M | Feb 24, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $202.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $206.80M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $208.90M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $253.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $255.20M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $257.30M | Feb 23, 2021 |
| FY2018 | Dec 31, 2018 | $196.10M | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $197.00M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $228.60M | Feb 26, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 8 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 23, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 8 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 23, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 72.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 72.30M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 73.50M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 74.10M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | 74.20M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 74.00M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 74.10M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | 74.10M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | 73.90M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 73.10M | Feb 26, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.20M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $59.10M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $57.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $54.10M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $51.10M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $48.10M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $45.10M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $42.10M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $39.10M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $35.80M | Feb 28, 2019 |